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Microvascular complications of type 1 diabetes, which primarily include diabetic kidney 
disease, retinopathy and neuropathy, are characterized by damage to the microvasculature 
of the kidney, retina and neurons. The pathogenesis of these complications is multifactorial, 
and several pathways are implicated. These complications are often silent during their early 
stages, and once symptoms develop, there might be little to be done to cure them.  
Thus, there is a strong need for novel biomarkers to identify individuals at risk of 
microvascular complications at an early stage and guide the implementation of new 
therapeutic options for preventing their development and progression.  
Recent advancements in proteomics, metabolomics and other ‘omics’ have led to the 
identification of several potential biomarkers of microvascular complications. However, 
biomarker discovery has met several challenges and, up to now, there are no new 
biomarkers which have been implemented into clinical practice. This highlights the need of 





• Early detection of microvascular complications is of paramount importance and new 
biomarkers are required to achieve that. 
• New ‘omics’-based biomarkers are promising, and they could be included in a multi-
biomarker approach together with traditional markers of complications to support 
early diagnosis and management of microvascular complications. 
• Many challenges remain in biomarkers discovery and translation into clinical 
practice, and future larger collaborative studies for a better characterisation of new 









Mortality rates in individuals with type 1 diabetes (T1D) still exceed that of the background 
population by 3-4 fold [1–3], even though over the last decades there have been key 
advancements in the management of this condition. The burden associated with T1D is 
largely due to the associated micro- and macro-vascular complications, which develop in a 
high percentage of patients after a variable diabetes duration [4,5].  
Prevention of vascular complications relies on the ability to identify high-risk individuals at an 
early stage when tissue damage may be more responsive to interventions and reversible [4–
6]. Many of the biomarkers currently in use do not allow for early diagnosis of vascular 
damage, thus highlighting the need for novel biomarkers reflecting earlier stages of the 
development of vascular complications, to identify subjects at risk and implement additional 
preventive strategies.  
Recent advancements in proteomics, metabolomics and other ‘omics’ and the integration of  
these different approaches continue to unveil new potential biomarkers in several fields, 
including T1D vascular complications [7,8].  
This review provides an overview of the state-of-the-art on biomarkers of microvascular 
damage, specifically in the context of T1D. The focus of the review is on the value of 
biomarkers of vascular complications and the challenges related to their development and 
implementation into clinical practice. Some examples of biomarkers identified during most 
recent years, mainly arising from the application of proteomics and metabolomics, are also 
provided. 
 
2. Diabetes microvascular complications  
Vascular complications of T1D are generally classified in microvascular, affecting small 
vessels in the retina, kidney and nerves, and primarily including diabetic kidney disease 
(DKD), diabetic retinopathy (DR), and diabetic neuropathy (DNeu), and macrovascular 
complications, such as cardiovascular, cerebrovascular and peripheral vascular disease, 
where large vessels are predominantly affected [4–6,9]. However, this is a simplified 
classification and it is important to bear in mind that microvascular damage can also occur in 
other tissues, such as the heart, brain, myocardium, skin [5,9]. Furthermore, significant 
associations between microvascular and macrovascular complications have been reported, 
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whereby patients with one complication often present a second one, suggesting common 
risk factors and/or underlining mechanisms [10]. Some of the common risk factors for 
vascular complications are hyperglycemia, dyslipidemia, hypertension, diabetes duration, 
smoking, overweight, insulin resistance [11]. Endothelial dysfunction has been suggested as 
one of the potential links between different vascular complications [12]. Inflammation and 
oxidative stress are two key mechanisms implicated in the pathogenesis of all vascular 
complications as well as of T1D comorbidities, such as hypertension and dyslipidemia [13]. 
Cardiovascular disease, mainly in the form of coronary artery disease, is the main cause of 
mortality in people with T1D [14]. However, there is also strong evidence that microvascular 
complications substantially contribute to morbidity and mortality in individuals with T1D 
[15–17]. This was recently confirmed by data from the large cohort with T1D from the Steno 
Diabetes Center, showing a 2.2-fold increased mortality rate in the presence of DKD and 1.7-
fold increase in individual with Dneu [18].  
 
2.1 Epidemiology, natural history and diagnosis 
2.1.1 Diabetes kidney disease 
DKD is one of the main microvascular complications affecting up to 50% of all people with 
T1D over the course of their lifetime [19]. DKD represents the leading cause of End Stage 
Renal Disease (ESRD) worldwide and a main determinant of cardiovascular disease and 
mortality [18,19]. DKD reflects structural and functional changes occurring in the kidney, 
manifesting as renal hemodynamic changes, progressive increases in albuminuria and 
decline in renal function, and hypertension. Major renal structural changes include 
mesangial expansion, glomerular and tubular basement membrane thickening and 
glomerular sclerosis [20]. Renal hemodynamic changes, oxidative stress, inflammation, 
hypoxia and abnormalities in the renin-angiotensin-aldosterone system (RAAS) are involved 
in the pathogenesis of DKD [21]. 
The most characteristic biomarker, currently in use for the diagnosis of DKD, is albuminuria, 
which is associated with renal disease progression and cardiovascular events [15]. In 
addition, glomerular filtration rate (GFR) is another renal marker currently in use [22,23]. 
However, there is ongoing debate on the sensitivity and specificity of these biomarkers and 
a strong need for new biomarkers reflecting earlier subclinical manifestations of DKD. 
2.1.2 Diabetic retinopathy 
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DR is the most common eye disease and the leading cause of blindness among patients with 
T1D and its overall prevalence is about 35% [24]. It occurs following damage in the retinal 
microvasculature, manifested as basement membrane thickening, increased capillary 
permeability, vascular tortuosity, retinal haemorrhage, microaneurysms, cotton-wool spots 
and lipid exudates [25]. These changes can be clinically silent for many years and then 
become evident as features of non-proliferative retinopathy. Further progression of retinal 
microvascular changes can lead to intravascular coagulation, resulting in retinal ischemia 
and consequent formation of new vessels within the retina. These new vessels are fragile, 
and their rupture leads to retinal bleeds and manifest as proliferative retinopathy. Fluid 
accumulation within the central neural retina, referred to as diabetic macular edema, 
manifests as abnormal retinal thickening and cystoid formation and is the most common 
cause of visual loss in individuals with DR [25]. 
Retinal fundus examination is the basis of current screening for DR; however, standard 
assessment can miss very early functional and structural abnormalities [23]. There are no 
circulating biomarkers of retinopathy currently in use. New non-invasive imaging 
techniques, such as retinal microvascular geometry assessment, are currently being 
explored to allow the identification of early damage within the retinal microcirculation [26]. 
However, at present, these new techniques are only for research use and not yet 
implemented into clinical practice.  
2.1.3 Diabetic neuropathy 
DNeu refers to a spectrum of various neurological disorders associated with diabetes. It is 
defined by a clinical or subclinical disorder, without any additional causes of peripheral 
neuropathy other than diabetes and can be either somatic or autonomic [5,27,28]. Chronic 
distal symmetric polyneuropathy is the most common form of DNeu and is characterized by 
symmetric damage of peripheral small sensory and large motor nerve fibers [27]. It occurs in 
about 20% of patients with T1D after a disease duration of 20 years and up to 50% at 10 
years of disease [29]. DNeu is a significant contributor to overall morbidity and mortality. Of 
note, about 50%–70% of non-traumatic amputations are due to this complication [29].  
The diagnostic approach is complicated and not well standardized and comprises clinical 
assessments based on signs, symptoms and questionnaires; instrumental tests, such as the 
10g monofilament or the gold standard nerve conduction studies [23,27]. However, the 
latter tests are labour intensive, time consuming, costly and not easily implementable in 
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daily clinical practice. Therefore, peripheral DNeu is often diagnosed late when irreversible 
nerve injury has occurred, and its first presentation may be with a diabetic foot ulcer.  Thus, 
an area of unmet need is the implementation of effective screening for early abnormalities 
preceding the appearance of overt clinical manifestations. 
Some new techniques, such as corneal confocal microscopy and point-of-care devices for an 
early diagnosis of peripheral neuropathy are currently being explored [27]. No circulating 
biomarkers are currently available in clinical practice to support the diagnosis and 
management of DNeu.  
 
2.2 Pathogenesis of microvascular complications  
The pathogenesis of microvascular complications is incompletely understood, but it is likely 
the result of an interplay between several metabolic and hemodynamic factors, which occur 
as a consequence of hyperglycemia, dyslipidemia, hypertension, genetic predisposing 
factors and other environmental factors [5,30]. 
Hyperglycemia is a key determinant of vascular complications of T1D, and there is extensive 
evidence showing that both acute and chronic hyperglycemia have a deleterious effect [30–
32]. Hyperglycemia contributes to the development of vascular complications through 
several mechanisms: activation of diacylglycerol-protein kinase C, polyol and hexosamine 
pathways; increased oxidative stress and advanced glycation end-products, subclinical 
inflammation, RAAS dysregulation. These factors can, in turn, induce diffuse altered blood 
flow, endothelial permeability, extravascular protein deposition and coagulation resulting in 
the progressive development of microvascular complications and organ dysfunction [30–
32].  
Of interest, recent animal studies have highlighted potential differences in the pathways 
activated by hyperglycemia in the context of each individual microvascular complication 
[33]. In addition to the main effect of hyperglycemia, altered lipid metabolism has also 
emerged as a key player in the pathogenesis of diabetic complications, with distinct 
contributing effects in the context of different vascular beds [33].  
Microvascular complications are characterized by a long subclinical phase before becoming 
clinically manifest [4]. Early functional and structural changes in the eyes, kidney and nerves 
can occur soon after diagnosis, but be silent for many years [4]. This highlights the 
importance of early detection of subclinical signs of complications to prevent their 
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progression. However, it is currently impossible to reliably predict when and who will 
develop any of the microvascular complications. Their early detection relies on the 
availability of sensitive and specific biomarkers, which should be easily implemented in daily 
clinical practice.  
The mechanisms implicated in the pathogenesis of microvascular damage can lead to an 
altered expression of local and circulating molecules, which could be used as biomarkers of 
disease development and progression, as well as potential targets for future interventions.  
 
3. The role of Biomarkers in the field of diabetic microvascular complications 
A biomarker is defined as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention” [34,35]. Biomarkers can provide a robust approach to 
understand the spectrum of a disease from the earliest silent signs up to the most advanced 
stages. The ideal biomarker should be readily quantifiable in accessible biological samples, 
such as blood or urines, be sensitive and specific and show a good correlation with the 
progression of the outcome of interest. It also needs to be economical and feasible to be 
measured in most clinical laboratories. (Box 1) 
In the context of microvascular complications, it is essential to discover new biomarkers 
which could allow the identification of vascular damage during its early subclinical phases, 
predict it progression and provide support for the development and implementation of 
tailored interventions. Sensitive and specific biomarkers could guide screening programmes, 
improve risk stratification, predict response to treatment as well as provide a way of 
monitoring response to treatment. (Figure 1) 
In clinical practice, the value of new biomarkers of vascular complications is to replace or 
improve the predictive value of markers currently in use, such as clinical and biochemical 
parameters or imaging tests, for an early identification of microvascular damage and predict 
those patients at risk of developing complications as well as those most at risk of 
progressing to more advanced stages [36]. From a research perspective, new biomarkers 
could help to understand signalling pathways related to microvascular damage and discover 
novel therapies to prevent and treat complications. New biomarkers could also support 
selection of participants for future clinical trials exploring new interventions and predict and 
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monitor response to treatment [37,38]. This would improve the power of future studies and 
their efficiency. 
Given the complexity and the multiple mechanisms and pathways implicated in the 
pathogenesis of microvascular complications, it is likely that there is not a single optimal 
diagnostic and prognostic biomarker, but more likely multiple biomarkers. The possibility to 
combine several different biomarkers in a multi-marker approach could improve the ability 
of detecting subjects most at risk and separate them from those at lower risk. 
Biomarkers discovery for microvascular complications has been based on hypothesis-based 
as well as hypothesis-free approaches [39]. Hypothesis-based approaches rely on the 
knowledge of the pathogenetic mechanisms implicated in the development of 
complications. Hypothesis-based biomarkers are primarily those reflecting biochemical 
consequences of the diabetes milieu, such as hyperglycemia-related pathways including 
inflammation, oxidative stress, fibrosis, hypoxia, mythocondrial dysfunction, or lipid-related 
pathways [30]. In the context of each individual complication, tissues-specific biomarkers 
may also be of enormous relevance, and this can include glomerular or renal tubular 
proteins, endothelial cell markers and nerve components. 
However, hypothesis-free technologies can provide additional support to identify novel 
biomarkers, and this is an emerging and active field for biomarkers discovery for vascular 
complications, which has been supported by recent advancements in proteomics, 
metabolomics, as well as genomics, transcriptomics, lipidomics and microRNA [40]. (Figure 
1) 
It is envisaged that a multi-omics approach could facilitate biomarkers discovery. Findings 
from different ‘omics’ and ‘non-omics’ approaches could be combined to generate scores 
and be included into predictive models together with clinical predictors to improve 
prediction of complications [41]. 
 
4. Challenges in biomarker discovery for diabetes microvascular complications 
The development of clinically relevant biomarkers of microvascular damage has been met 
with numerous challenges, many of which are in common with other fields.  
One key issue is biomarkers tissue specificity. It would be optimal to measure biomarkers 
directly in the tissues affected by the disease of interest. For vascular complications this 
implies using renal tissue obtained through kidney biopsies, retinal or nerves biopsies, which 
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are not easy to obtain and, for research purposes, pose relevant ethical considerations. 
Thus, so far biomarkers have been assessed mainly in biological fluids, such as blood or 
urine [42]. However, the obvious question is as to whether circulating biomarkers reliably 
reflect tissue mechanisms and local concentrations of any specific biomarker. To overcome 
this issue, alternative potential sources of biomarkers have been explored, such as tears in 
the context of DR [43].  
Biomarkers discovery can be difficult due to different phenotypes associated with the 
individual diabetic vascular complications. For DKD, for example, studies have explored 
biomarkers in relation to different renal outcomes, such as GFR decline, ESRD, micro- or 
macroalbuminuria [42]. For DR, different studies have recruited populations with different 
phenotypes, including non-proliferative retinopathy, proliferative retinopathy, macular 
edema [44]. This can explain discordant findings between studies and make comparisons 
difficult. 
In addition, although one can expect that some biomarkers, such as those reflecting 
inflammation, oxidative stress, endothelial dysfunction, could be in common to all 
microvascular complications, most of them are likely tissue specific [28,42,44]. Given the 
evidence that microvascular complications often tend to co-occur in the same individuals, it 
would be of interest to explore biomarkers in individual with one vs those with multiple 
complications, as well as the potential additional contribution of the effect of comorbidities, 
such as hypertension or dyslipidemia on biomarkers. 
In addition, for any specific complication, there are differences in biomarkers in individuals 
with T1D vs type 2 diabetes (T2D) and so far there have been more studies in adults with 
T2D [42]. 
Another important aspect to consider is that most of the studies on biomarkers for diabetic 
complications have been performed in adult populations. In general, biomarkers discovery 
in pediatrics has been limited, although they will be invaluable in this age group for the early 
diagnosis and prevention of chronic conditions, such as diabetes and its complications [45]. 
Given that biomarkers can show age-specific differences, those identified in populations of 
adults with diabetes cannot necessarily be translated to youth with diabetes.  
Biomarker discovery requires large sample sizes to have enough power, mainly when 
exploring multiple biomarkers through ‘omics’ approaches. In addition, biomarker utility 
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needs to be confirmed in two or more independent populations, including discovery and 
validation cohorts [46].  
Differences in assays and mass spectrometry approaches across different laboratories can 
introduce a source of bias in biomarker measurements. Therefore, once a biomarker has 
been identified, harmonization of techniques for measurement and quality control 
measures, as well as defining reference values are essential to reduce measurement 
variability [47]. A wider availability of techniques, such as mass spectrometry and magnetic 
resonance spectroscopy, and expertise with them in clinical laboratories, are other essential 
steps to move towards the translation of biomarkers into clinical practice. Standardized 
procedures are also required in terms of sample collection, handling and storage.  
Furthermore, the added value of a novel biomarker in clinical practice compared with 
existing markers should also be carefully evaluated. New biomarkers can be more expensive 
than traditional markers used for screening or diagnostic purposes. Although there have 
been enormous progresses with ‘omics’ technologies, they remain costly and not yet of 
unlimited access. Therefore, for any new biomarker there is a need to assess its 
performance versus existing clinical predictors and biomarkers. It is essential to analyze the 
cost-effectiveness of their introduction into clinical practice to reduce risk of complications 
and improve patients’ outlook.  
 
5. Where are we in biomarkers discovery for microvascular complications? 
5.1 Diabetic kidney disease 
Over the last decades, several studies have assessed potential new biomarkers which could 
replace GFR and urinary albumin excretion or improve their predictive value for the 
identification of DKD and prediction of progression towards ESRD. Biomarkers of DKD have 
been extensively reviewed elsewhere [42,48]. Here, some key aspects related to biomarkers 
discovery will be reviewed along with some examples of relevant biomarkers identified so 
far.  
Development and validation studies for DKD biomarkers in patients with T1D have been 
based on biological samples (urines, blood), with only few studies being based on kidney 
biopsy tissues. Most studies have been performed in cohorts of adults with T2D, and fewer 




The approaches used for DKD biomarkers discovery have been different, going from 
investigations of single biomarkers in biological samples to multiple biomarkers assessed in 
the same samples, individually or as part of panels, and more recently to proteomic- and 
metabolomics-based approaches [42,48].  
When interpreting the available results on biomarkers for DKD it is important to take into 
account significant differences between studies in terms of characteristics of the study 
populations, i.e. stages of DKD, study design and selected renal outcomes, and the 
adjustments made in the predictive models, which not always have allowed for known 
predictors of DKD [42,48]. The search for new biomarkers has focused mainly on circulating 
molecules in the blood or urine able to improve prediction of clinically significant outcomes 
such as ESRD, marked decline in GFR or death. There remains a strong need for biomarkers 
reflecting early structural and functional changes occurring in the kidney [49]. 
Different approaches have been used in different studies and this is another factor 
complicating comparisons and explaining heterogeneous findings when comparing studies. 
These have included: hypothesis-based approaches, where single or multiple biomarkers 
have been assessed using ELISA or multiplexed platforms, and proteomics and 
metabolomics studies, mainly based on based on mass spectrometry and nuclear magnetic 
spectroscopy [42,48].  
The DKD biomarkers identified so far belong to different categories: glomerular and renal 
tubular biomarkers, inflammation-, oxidative stress-, fibrosis-related biomarkers as well as 
cardiovascular biomarkers [42,48,50]. 
Several inflammatory biomarkers have been investigated in relation to DKD [51]. A recent 
systematic review and meta-analysis [52] provided an updated overview on the association 
between circulating tumor necrosis factor receptors (TNFRs), which have been widely 
studied in relation to DKD, and the risk of DKD progression as well as cardiovascular disease 
events and mortality in patients with diabetes. Overall the analysis showed a 2-fold 
increased risk of DKD progression per doubling increase in TNFR1 and TNFR2. In a recent 
study, Niewczas et al [53] quantified circulating concentrations of 194 inflammatory 
proteins in 3 cohorts with diabetes totalling 525 participants. Using a global proteomic 
profiling approach, 17 inflammatory proteins, defined as ‘kidney risk inflammatory signature 
(KRIS)’, were associated with a 10-year risk of developing ESRD. Of note, the protein 
signature was enriched in TNFR superfamily members [53]. All identified proteins had a 
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systemic, non-kidney source, providing strong evidence for a role of inflammation in the 
pathogenesis of DKD and a target for future intervention strategies. 
Proximal tubular proteins, such as urinary Kidney Injury Molecule-1, Neuthrophil gelatinase-
associated lipocalin, Liver-type fatty acid-binding protein have been associated with a faster 
decline in GFR in adults with T1D [54,55]. Studies have also highlighted the role of 
cardiovascular disease biomarkers as being associated with declining renal function, such as 
high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide [56,57].  
Urinary proteomics is a promising tool to identify biomarkers of DKD [48,58]. Recent urinary 
proteomics studies in patients with diabetes have highlighted some promising 
proteins/peptides associated with renal outcomes and reflecting potential pathogenetic 
mechanisms implicated in DKD [48,58].  
Of particular interest is CDK273, a panel of 273 urinary biomarkers, discovered in an original 
comparison of the urinary proteome of 379 healthy participants and 230 participants with 
chronic kidney disease related to different renal conditions, which represents a good 
example on how to combine multiple biomarkers into a ‘classifier’ [59,60]. The CDK273 
classifier has been associated with progression of albuminuria and loss of renal function in 
retrospective cohorts, mainly with T2D [42]. More recently, in a recent large prospective 
multicentre study (PRIORITY), the CKD273 classifier was used for risk stratification in 
individuals with normoalbuminuria and T2D [38]. A high-risk score based on CDK273 was 
able to predict progression of microalbuminuria, independently of clinical characteristics, 
and a 30% decline in GFR in those participants at risk of microalbuminuria [38]. However, 
the mineralocorticoid receptor antagonist spironolactone was not shown to delay or 
prevent development of microalbuminuria in those identified to be at high risk of 
progression by the CKD273 classifier [38]. Further studies are required to confirm the value 
of this classifier in T1D and explore ways of integrating it with other markers into clinical 
practice.  
Metabolomics has also been applied in the field of DKD and unveiled several metabolites 
mainly represented by products of lipid metabolism, branched chain and aromatic amino 
acids, citric acid cycle metabolites related to mitochondrial dysfunction [60,61]. 
5.2 Diabetic retinopathy 
Biomarkers of DR have been explored in blood samples, and in more specific fluids/tissues, 
such as vitreous humour, aqueous humour and retina tissue [43,44,62]. The retina, vitreous 
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and aqueous humours represent great sources to understand the pathogenesis of DR and 
identify biomarkers. However, their collection requires invasive procedures, which could be 
acceptable if performed for clinical indications, such as surgery for managing retinal 
diseases, but not for diagnostic or screening purposes. Most studies using these tissues have 
been performed in animal models or post-mortem in humans [43,44,62].  
Of interest, over recent years, there has been a focus on tears as a potential source of new 
biomarkers of DR [43,44]. The main advantage of tear samples is that they can be collected 
noninvasively, they contain a relatively high concentration of proteins and tear proteome 
correlates with disease progression [43,44]. Starting from studies performed in 2012, a 
relevant number of proteins in the tears have been associated with different stages of DR. 
These include, among others, lipocalin A, lysozyme C, lipophilin A, immunoglobulin lambda 
chain, lactotransferrin, β-2-microglobulin [44].  
Many systemic biomarkers have been associated with different stages of DR. Most of them 
are inflammatory molecules and endothelial dysfunction markers. This underscores a key 
role of inflammation in the pathogenesis of DR. Among novel biomarkers, it is important to 
mention VEGF, because it is implicated in retina neovascularization. Its key role into the 
pathogenies of proliferative retinopathy has led to a new intervention for this complication, 
with anti-VEGF drugs [63]. Additional biomarkers linked to DR are advanced glycation end 
products and angiogenic proteins, including fibroblast growth factor-21, adiponectin, 
cystatin C [44].  
Metabolomics studies have also been performed for DR and have mainly highlighted 
abnormalities in metabolites from different pathways, including amino acids, such as 
tryptophan metabolites, indoleamine 2,3-dioxygenase, fatty acids, glucose metabolism [61].  
As for DKD, different studies have led to discordant results due to various factors, such as 
differences in study populations and stages of DR under investigations. Different approaches 
have been used in different studies, including single or panel of biomarkers as well as wider 
approaches, such as proteomic and metabolomics, and this represents another source of 
variability between studies [43,44,61,64].  
5.3 Diabetic neuropathy 
A comprehensive review of the main biomarker discovery studies for DNeu has been 
recently published [28]. One key aspect is that, compared to DKD and DR, there are fewer 
data on biomarker discovery for DNeu based on hypothesis-free approaches using 
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proteomics or metabolomics. However, there are growing data on new potential imaging 
techniques, which could support and improve diagnosis and management of this 
complication in the future [28].  
Systemic biomarkers of oxidative stress, inflammation, and vascular activation have been 
associated to peripheral DN. Pro‐inflammatory cytokines, such as TNF‐α, IL‐1, IL‐6, IL‐8, 
monocyte chemoattractant protein‐1 and C‐reactive protein, vascular cell adhesion 
molecule‐1, E‐selectin and chemokines show an increased expression in patients with 
diabetic peripheral neuropathy [65]. Biomakers such as ICAM‐1 and IL‐1 receptor have been 
associated with progression of peripheral DNeu [66].  
A promising novel biomarker of DNeu is Nrf2, a molecule which acts as a link in various 
inflammatory and apoptotic pathways impacting progression of DR [67]. There is evidence 
suggesting that while acute hyperglycemia increases the expression of Nrf2, chronic 
hyperglycemia decreases its expression. This downregulation of Nrf2 causes various 
microvascular changes, which result in diabetic neuropathy. Nrf2 activators have been 
suggested as a therapeutic potential for the treatment of diabetic neuropathy [67]. Of 
interest, preliminary data suggest that levels of substance P, which is implicated in 
maintaining corneal nerve health, in the tear film, are reduced in individuals with T1D and 
this is associated with both corneal changes and peripheral DNeu [68].  
Further studies are required to confirm these new promising biomarkers along with a wider 
application of omics approaches to identify additional early biomarkers of DN. 
 
6. Summary and Conclusions 
Diabetic microvascular complications are often asymptomatic during their early stages, and 
once symptoms develop, there might little to be done to cure them. Therefore, there is 
clearly a need for novel biomarkers with high sensitivity and specificity for predicting the 
development and progression of vascular complications. The identification of reliable 
biomarkers, in addition to providing useful tools for early detection of complications and 
risk stratification, could also bring new insights into pathogenetic mechanisms, and lead to 
new therapeutic options.  
During recent years, several new biomarkers have been identified, although often with 
discordant findings across studies and different populations with diabetes. Disappointingly, 
none of the discovered biomarkers have been implemented into clinical practice. In my 
15 
 
opinion there are still some key steps to be made before translation from bench to bedside 
can occur. First, there is a clear need of further larger collaborative studies for biomarkers 
discovery and validation based on standardized protocols for sample collection and 
processing, and data analysis. Well characterized study populations with a wider age range 
should be included in future studies.  
The most promising approach to improve early detection and management of microvascular 
complication will likely rely on the integration of multiple biomarkers, reflecting different 
pathways and mechanisms implicated in microvascular damage, and emerging from 
different approaches, such as proteomics, metabolomics, genomics, by generating a 
biomarker score or classifier. However, omics technologies remain costly and of limited 
accessibility, and there will be a need of health economics assessments before 
recommending novel omics-based biomarkers for routine use. 
This highlights the need of further work in this area, which is essential to move towards a 
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Box 1. Characteristics of an ideal biomarker for microvascular complications: 
1. Highly sensitive and specific  
2. Correlated with the severity of microvascular damage 
3. Non-invasive 
4. Easy to measure and cost-effective 
5. Applicable across different populations 
6. Provide risk stratification and prognostic information 
7. Identify possible pathogenetic mechanisms and targets for new interventions 
8. Support stratification for interventions 


























Figure 1. Model of multi-biomarkers development for microvascular complications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
